Reply by the authors of the original article.
Adil
A
Al-Lawati
Venkitraman
V
Muthuswamy
D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D019106:Postoperative Hemorrhage / Q000628:therapy*
D000933:Antifibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin